Painful Diabetic Neuropathy Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Pregabalin Sustained-Release Tablets for the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
This study is designed to evaluate the efficacy and safety of pregabalin extended-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Pregabalin has been approved in more than 130 countries for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and neuralgia associated with spinal cord injury. Pregabalin extended-release tablets were administered once daily, as a single dose after dinner. Compared with pregabalin capsule formulation, it reduces the frequency of medication and improves patient compliance.
This is a multicenter, randomized, double-blind, placebo-controlled trial, the study was designed to evaluate the efficacy and safety of pregabalin sustained-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. The study includes a screening period (3 weeks, including baseline/run-in period), a treatment period (titration period, fixed dose period and withdrawal period), and a follow-up period. During the treatment period participants will receive pregabalin sustained-release tablets/placebo as daily treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT05476276 -
EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy
|
Phase 2 | |
Recruiting |
NCT05480228 -
EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA
|
Phase 2 | |
Unknown status |
NCT01125215 -
Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05937984 -
Treatment for Painful Diabetic Neuropathy
|
N/A | |
Recruiting |
NCT05080530 -
Vitamin D and Painful Diabetic Neuropathy
|
N/A | |
Completed |
NCT04005287 -
A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy
|
Phase 2 | |
Recruiting |
NCT03331614 -
An Evaluation of an SCCD on the Symptomatology of Painful DPN
|
N/A | |
Recruiting |
NCT03700528 -
The Development of Contextual Cognitive Behavioural Approach to PDN
|
N/A | |
Recruiting |
NCT04689984 -
The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
|
Phase 2/Phase 3 | |
Recruiting |
NCT04689971 -
The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
|
Phase 2/Phase 3 | |
Recruiting |
NCT04689958 -
The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
|
Phase 2/Phase 3 | |
Completed |
NCT03749642 -
Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy
|
Phase 2 | |
Not yet recruiting |
NCT04087941 -
Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial
|
Phase 2 | |
Terminated |
NCT01129960 -
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
|
Phase 3 | |
Terminated |
NCT01056315 -
A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
|
Phase 2 | |
Completed |
NCT00980746 -
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT04786340 -
A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT03769675 -
Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation
|
N/A | |
Completed |
NCT03755934 -
Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy
|
Phase 2 |